Search Results for

S2007

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Continue Reading »

---

EFC15935

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)

Continue Reading »

---

NRG-BR007

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Continue Reading »

---

EA1181

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Continue Reading »

---

A011801

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Continue Reading »

---

S1706

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Continue Reading »

---

A191901

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Continue Reading »

---

SGNTUC-016

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Continue Reading »

---

EAZ171

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Continue Reading »

---

URCC 18007

Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors

Continue Reading »

---

Search Again

• All Trial Categories Anal  (2) Bladder/Urinary Tract Cancer  (7)    Metastatic  (3)    Neoadjuvant  (4) Brain  (7)    Glioblastoma Multiforme (GBM)  (3)    Other Brain Tumors  (3) Breast  (17)    1st Line Metastatic Breast, Metastasis at Presentation or Progression of earlier Disease  (4)    2nd Line Metastatic Breast, Progressive Disease Following 1st Line Therapy  (1)    Breast Cancer Adjuvant  (3)    DCIS/LCIS  (1) Cancer Control/Symptom Management  (19) Colorectal Cancer  (8)    Metastatic  (3)    Rectal Neoadjuvant  (1) Esophageal Cancer  (2) Gall Bladder/ Biliary Tract Cancer  (2) Gastric Cancer  (1)    Metastaic Gastric Cancer  (1) Head/Neck Cancer  (5)    Resectable Oral Cavity Cancer  (1)       Primary Chemoradiation Regimens  (1) Leukemia  (6)    Acute Myeloid Leukemia (AML)  (1)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (3) Liver/Hepatocellular Carcinoma  (1) Lung Cancer  (26)    Non-Small Cell Lung Cancer  (18)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (5)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (3)       Adjuvant Treatment for Resected NSCLC  (3)    Small Cell Lung Cancer  (8)       Extensive Stage SCLC  (5) Lymphoma  (5)    Non-Hodgkin’s Lymphoma  (2)       Follicular Lymphoma  (1)          Relapsed/Refractory  (1) MATCH Trial  (1) MDS  (3) Melanoma  (5)    Metastatic  (2) Merkel Cell Carcinoma  (1) Multiple Myeloma  (2) Pancreatic  (4)    Metastatic Disease  (2) Prostate  (10) Renal Cell/Kidney Cancer  (4)    Locally Advanced/Metastatic  (4) Sarcoma  (2) Small Bowel  (1)